Evercore ISI reissued their buy rating on shares of Adamas Pharmaceuticals (NASDAQ:ADMS) in a report released on Monday, AnalystRatings.com reports. They currently have a $55.00 price target on the specialty pharmaceutical company’s stock.

ADMS has been the topic of several other reports. Zacks Investment Research cut shares of Adamas Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, July 30th. HC Wainwright lowered their price target on shares of Adamas Pharmaceuticals from $40.00 to $30.00 and set a buy rating on the stock in a research note on Tuesday, May 28th. ValuEngine raised shares of Adamas Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, August 1st. Finally, Mizuho reaffirmed a sell rating and set a $5.00 price target on shares of Adamas Pharmaceuticals in a research note on Wednesday, April 24th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $21.81.

Shares of ADMS opened at $6.06 on Monday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 6.86 and a current ratio of 7.03. The firm has a fifty day moving average price of $6.03. Adamas Pharmaceuticals has a 1 year low of $4.20 and a 1 year high of $23.45.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.08. The company had revenue of $12.69 million for the quarter, compared to analysts’ expectations of $12.62 million. Adamas Pharmaceuticals had a negative net margin of 241.41% and a negative return on equity of 130.39%. As a group, equities research analysts expect that Adamas Pharmaceuticals will post -3.74 EPS for the current year.

Large investors have recently bought and sold shares of the company. Alps Advisors Inc. grew its stake in shares of Adamas Pharmaceuticals by 4.5% during the 1st quarter. Alps Advisors Inc. now owns 66,026 shares of the specialty pharmaceutical company’s stock worth $469,000 after purchasing an additional 2,860 shares during the period. BlackRock Inc. grew its stake in shares of Adamas Pharmaceuticals by 9.3% during the 4th quarter. BlackRock Inc. now owns 2,064,758 shares of the specialty pharmaceutical company’s stock worth $17,633,000 after purchasing an additional 174,844 shares during the period. Bingham Osborn & Scarborough LLC grew its stake in shares of Adamas Pharmaceuticals by 8.8% during the 1st quarter. Bingham Osborn & Scarborough LLC now owns 145,913 shares of the specialty pharmaceutical company’s stock worth $1,037,000 after purchasing an additional 11,805 shares during the period. Deutsche Bank AG grew its stake in shares of Adamas Pharmaceuticals by 506.7% during the 4th quarter. Deutsche Bank AG now owns 274,050 shares of the specialty pharmaceutical company’s stock worth $2,339,000 after purchasing an additional 228,883 shares during the period. Finally, SG Americas Securities LLC grew its stake in Adamas Pharmaceuticals by 37.5% in the 1st quarter. SG Americas Securities LLC now owns 33,766 shares of the specialty pharmaceutical company’s stock valued at $240,000 after acquiring an additional 9,213 shares during the last quarter. 76.49% of the stock is currently owned by institutional investors and hedge funds.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

See Also: The mechanics of the bid-ask spread in trading

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.